HER2 Breast Cancer

Latest News

Microscopic view of metastatic breast cancer cells development and progression | Image Credit: © ratirath - stock.adobe.com
Study Shows Real-World Outcomes of First-Line Palbociclib Plus Fulvestrant in HR+, HER2– Metastatic Breast Cancer

January 18th 2025

Palbociclib is an oral CDK4/6 inhibitor that was approved by the FDA in 2017.

FDA approval seal -- Image credit: Aquir | stock.adobe.com
FDA Approves Dato-DXd for Adults With Unresectable or Metastatic HR+, HER2- Breast Cancer

January 17th 2025

Breast cancer cells | Image Credit: © Jack - stock.adobe.com
Metronomic Capecitabine With an Aromatase Inhibitor Demonstrates Safety, Efficacy in Treatment of HR+, HER2– Metastatic Breast Cancer

January 15th 2025

Photo of breast cancer shows positive result of HER2 stain, photo under microscope, magnification 400x
FDA Grants Additional Fast Track Designation to Emiltatug Ledadotin to Treat HER2 Low, HER2-Negative Breast Cancer

January 14th 2025

Wooden blocks spelling HER2+ | Image Credit: © AnnJane - stock.adobe.com
Palbociclib Combination Therapy Improves Outcomes for HR-positive, HER2-positive Metastatic Breast Cancer

January 8th 2025

<12345